These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 29018684)
21. Visual and anatomic outcomes of aflibercept treatment in treatment-naive patients with neovascular age-related macular degeneration; real-life data over 24 months. Makri OE; Tsapardoni FN; Tsekouras IK; Lagogiannis AP; Chairas N; Pallikari A; Pagoulatos DD; Georgakopoulos CD Hell J Nucl Med; 2019; 22 Suppl 2():55-62. PubMed ID: 31802046 [TBL] [Abstract][Full Text] [Related]
22. Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results. Homer N; Grewal DS; Mirza RG; Lyon AT; Gill MK Eye (Lond); 2015 Sep; 29(9):1152-5. PubMed ID: 26021870 [TBL] [Abstract][Full Text] [Related]
23. Short-term outcomes of switching anti-VEGF agents in eyes with treatment-resistant wet AMD. Batioglu F; Demirel S; Özmert E; Abdullayev A; Bilici S BMC Ophthalmol; 2015 Apr; 15():40. PubMed ID: 25885684 [TBL] [Abstract][Full Text] [Related]
24. Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Schmidt-Erfurth U; Kaiser PK; Korobelnik JF; Brown DM; Chong V; Nguyen QD; Ho AC; Ogura Y; Simader C; Jaffe GJ; Slakter JS; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Soo Y; Anderesi M; Sowade O; Zeitz O; Norenberg C; Sandbrink R; Heier JS Ophthalmology; 2014 Jan; 121(1):193-201. PubMed ID: 24084500 [TBL] [Abstract][Full Text] [Related]
25. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept. Chen YY; Chang PY; Wang JK Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640 [TBL] [Abstract][Full Text] [Related]
26. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539 [TBL] [Abstract][Full Text] [Related]
27. One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Arcinue CA; Ma F; Barteselli G; Sharpsten L; Gomez ML; Freeman WR Am J Ophthalmol; 2015 Mar; 159(3):426-36.e2. PubMed ID: 25461263 [TBL] [Abstract][Full Text] [Related]
28. Bevacizumab dosing every 2 weeks for neovascular age-related macular degeneration refractory to monthly dosing. Mimouni M; Meshi A; Vainer I; Gershoni A; Koren T; Geffen N; Nemet AY; Segal O Jpn J Ophthalmol; 2018 Nov; 62(6):652-658. PubMed ID: 30269186 [TBL] [Abstract][Full Text] [Related]
29. Two-year functional and anatomical results after converting treatment resistant eyes with exudative age-related macular degeneration to aflibercept in accordance with a treat and extend protocol. Jørstad ØK; Faber RT; Moe MC Acta Ophthalmol; 2017 Aug; 95(5):460-463. PubMed ID: 28556485 [TBL] [Abstract][Full Text] [Related]
30. Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study. Kim JH; Lee TG; Chang YS; Kim CG; Cho SW Br J Ophthalmol; 2016 Dec; 100(12):1634-1639. PubMed ID: 26951770 [TBL] [Abstract][Full Text] [Related]
31. Initial utilization of aflibercept in exudative age-related macular degeneration. Cho H; Weber ML; Shah CP; Heier JS Eur J Ophthalmol; 2014; 24(4):576-81. PubMed ID: 24706352 [TBL] [Abstract][Full Text] [Related]
32. The results of aflibercept therapy as a first line treatment of age-related macular degeneration. Unsal E; Cubuk MO J Curr Ophthalmol; 2019 Mar; 31(1):66-71. PubMed ID: 30899849 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability. Hata M; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ooto S; Tamura H; Nakanishi H; Takahashi A; Yoshikawa M; Yoshimura N Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):7874-80. PubMed ID: 25395483 [TBL] [Abstract][Full Text] [Related]
34. Long-Term Results of Pro Re Nata Regimen of Aflibercept Treatment in Persistent Neovascular Age-Related Macular Degeneration. Muftuoglu IK; Arcinue CA; Tsai FF; Alam M; Gaber R; Camacho N; You Q; Freeman WR Am J Ophthalmol; 2016 Jul; 167():1-9. PubMed ID: 27049000 [TBL] [Abstract][Full Text] [Related]
35. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. Gillies MC; Hunyor AP; Arnold JJ; Guymer RH; Wolf S; Ng P; Pecheur FL; McAllister IL JAMA Ophthalmol; 2019 Apr; 137(4):372-379. PubMed ID: 30676617 [TBL] [Abstract][Full Text] [Related]
36. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results. Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967 [TBL] [Abstract][Full Text] [Related]
37. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration. Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442 [TBL] [Abstract][Full Text] [Related]
38. [Switching Therapy from Ranibizumab and/or Bevacizumab to Aflibercept in Neovascular Age-Related Macular Degeneration (AMD): One-Year Results]. Pfau M; Fassnacht-Riederle HM; Freiberg FJ; Wons JB; Wirth M; Becker MD; Michels S Klin Monbl Augenheilkd; 2016 Aug; 233(8):945-50. PubMed ID: 27123887 [TBL] [Abstract][Full Text] [Related]